Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Benefit Of Rituximab Addition To High-Dose Programs With Autograft For B-Cell Lymphoma: A Multicenter Gitil Survey On 957 Patients.

Corrado Tarella,Manuela Zanni,Michele Magni,Fabio Benedetti,Tiziano Barbui,Mario Boccadoro, Katia Patti, Fabio Ciceri,Andrea Gallamini,Sergio Cortelazzo,Valerio Zoli,Salvatore Mirto,Roberto Passera,Paolo Corradini,Giovanni Pizzolo,Alessandro M. Gianni,Alessandro Rambaldi

BLOOD（2006）

Cited 4|Views14
No score
Abstract
Background: The outcome of B-cell lymphoma has definitely improved since the introduction of the anti-CD20 Rituximab, which can be effectively combined into conventional chemotherapy regimens. Rituximab can also be added to high-dose chemotherapy programs with autograft. However, the clinical benefit of combining Rituximab and autograft-based programs has not been proved yet. This issue is addressed in the present study.
More
Translated text
Key words
rituximab addition,high-dose,b-cell
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined